BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Bayer and NextRNA Therapeutics Partner to Develop Novel Small Molecule Drugs Targeting Long Non-Coding RNA in Cancer

by BiopharmaTrend   •   Aug. 28, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Bayer and NextRNA Therapeutics have entered a strategic partnership to develop a new class of small molecule drugs targeting cancers driven by dysregulated long non-coding RNA (lncRNA). The collaboration could result in a financial commitment exceeding $547 million, including an upfront payment, though specific details of the payment were not disclosed.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The partnership leverages NextRNA’s proprietary technology to advance two small molecule drug programs aimed at addressing cancers with significant unmet medical needs. The initial program is already in the preclinical testing phase at NextRNA. Bayer retains the option to select a second target for joint development.

While both companies have kept details about the specific cancer types and drug targets under wraps, they emphasized their focus on indications with a high unmet need. The collaboration represents a significant step in exploring the therapeutic potential of long non-coding RNA (greater than 200 nucleotides), a category of RNA that constitutes the majority of transcribed DNA but does not code for proteins.

See also: 14 Cutting-Edge Startups Focusing On RNA Research

NextRNA, founded in 2022 with $56 million in initial funding, is built on the pioneering research of Dr. Carl Novina of the Dana-Farber Cancer Institute, who co-founded the company. It applies its unique platform and capabilities to identify and disrupt lncRNA-RBP (RNA-binding protein) interactions with small molecules. Central to this approach is NextRNA's proprietary computational engine, NextMAP™, which identifies disease-driving lncRNAs across various conditions. The platform leverages deep expertise in lncRNA biology to validate the pathological mechanism of action, focusing on the interaction domains between lncRNAs and RBPs to guide drug discovery efforts.

In the drug development process, NextRNA utilizes a range of biochemical, biophysical, and chemical techniques to design functional small molecules. These molecules are engineered to inhibit the function of lncRNAs by disrupting their interactions with RBPs, offering a differentiated approach that allows for targeting either the lncRNA side or the RBP side of the interaction.

This partnership between Bayer and NextRNA underscores a growing focus on lncRNA as a novel target class in oncology, with the potential to open up new therapeutic avenues for cancers with few existing treatment options.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.